#Sepsis Diagnostics Market Forecast 2028 | Explore Tumblr Posts and Blogs

marketresearchstrategy · 3 years

Text

Biological Safety Cabinet Industry Supply Chain Analysis, Growth Opportunities, Top Companies, Revenue Growth and Business Development Report by 2027

Reports and Data has recently published a research report on global Biological Safety Cabinet market forecast to 2028. The report offers detailed overview of the market with recent market dynamics and industrial status. The report provides details about market size, market restraints, drivers, challenges, growth opportunities, and top companies in the market. The report also highlights about changes in the market dynamics due to outbreak of the COVID-19 pandemic. The report further provides details about each segments and regions covered in the global Biological Safety Cabinet market. The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/52

The pharmaceutical and healthcare sector has witnessed drastic changes in the recent years primarily due to growing prevalence of diseases, technological advancements in medicine, and increasing investments in research and development activities. The global Biological Safety Cabinet market is expected to reach USD XX Billion in 2028 from USD XX Billion in 2020 at a CAGR of XX%. Increasing investments in pharmaceutical sector, drug discovery developments, funding by public and private sectors are also boosting market revenue growth. In addition, availability of latest technology in several developed and developing countries, improvements in healthcare infrastructures and growing adoption of rapid testing and point-of-care diagnosis are further fueling market growth. In addition, constant demand for various medications, and devices is expected to continue to benefit leading companies during the ongoing pandemic. Increasing demand for home care settings, growing need for early diagnosis and increasing adoption of precision medicine are fueling market growth.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/52

Competitive Landscape:

The report also covers SWOT examination and Porter’s Five Forces analysis to offer details about leading players. The key players in the market are focusing on developing new strategies such as mergers and acquisition, joint ventures, new product launches, agreements, and partnerships to retain their market position and expand their product base.

Leading companies operating in the market and profiled in the report include:

Thermo Fisher Scientific

Labconco

Esco Micro

The Baker Company

Kewaunee Scientific

NuAire

Germfree Laboratories

Cruma

Air Science

Berner International

BIOBASE

Azbil Telstar

To know more about the report @ https://www.reportsanddata.com/report-detail/biological-safety-cabinet-market

The report further offers insights of the market segments based on product type, applications, end users, and 5 major regions covered in the global Biological Safety Cabinet market.

Biological Safety Cabinet Market Segmentation:

Product Type Outlook (Revenue, USD Million; 2017-2027)

Class II Type A

Class II Type B

Application Outlook (Revenue, USD Million; 2017-2027)

Biopharmaceutical and Chemical Companies

Labs for Diagnostics & Testing

Organizations for Academic & Science

Regional Outlook:

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

U.S.

Canada

Mexico

Germany

U.K.

Italy

France

BENELUX

Rest of Europe

China

India

Japan

South Korea

Rest of APAC

Brazil

Rest of LATAM

Saudi Arabia

A.E.

South Africa

Rest of MEA

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/52

Browse More Details:

Sepsis Therapeutics Market: https://www.reportsanddata.com/report-detail/sepsis-therapeutics-market Canine Influenza Vaccine Market: https://www.reportsanddata.com/report-detail/canine-influenza-vaccine-market

Medical Aesthetics Market: https://www.reportsanddata.com/report-detail/medical-aesthetics-market

Disposable Nursing Pad Market: https://www.reportsanddata.com/report-detail/disposable-nursing-pad-market

Breast Pump Market: https://www.reportsanddata.com/report-detail/breast-pump-market

0 notes

tritonmarketresearch · 3 years

Text

The Global Sepsis Diagnostics Market to Expand at CAGR of 8.18% by 2028

Triton Market Research presents the Global Sepsis Diagnostics Market segmented by Diagnostic Method (Automated Diagnostics, Conventional Diagnostics), Pathogen (Fungal Sepsis, Gram-Positive and Gram-Negative Bacterial Sepsis, Other Pathogens), Technology (Molecular Diagnostics, Microbiology, Immunoassay, Other Technologies), Testing Type (Point-of-Care Testing, Laboratory Testing), Product (Instruments, Blood Culture Media, Assay Kits & Reagents), and Geography (Asia-Pacific, Middle East and Africa, Europe, North America, Latin America). The report also discusses the Market Summary, Industry Outlook, Impact of COVID-19, Key Insights, Porter’s Five Forces Model, Market Attractiveness Index, Vendor Scorecard, Key Market Strategies, Drivers, Restraints, Opportunities, Competitive Landscape, Research Methodology & Scope, Global Market Size, Forecasts & Analysis (2021-2028).

Request a Free Sample:

https://www.tritonmarketresearch.com/reports/sepsis-diagnostics-market#request-free-sample

Triton Market Research’s report suggests that the global sepsis diagnostics market is anticipated to observe a surge at a CAGR of 8.18% over the forecasting period 2021-2028.

Sepsis refers to a condition that emerges as a result of the body’s response to pathogenic microorganisms in the blood. Several companies are taking initiatives to develop new technologies to address this condition.

The rising government initiatives for research activities related to sepsis are creating several opportunities for the global market over the considered phase. Over the years, there has been a tremendous rise in sepsis cases, owing to the increasing geriatric population and high risk of sepsis among patients undergoing an organ transplant. As per NHS, sepsis is a rare but severe complication of an infection, leading to organ failure if not remedied. Hence, these factors increase the need for research activities to develop new treatments. However, the high cost of the instrument, coupled with reimbursement issues, is restricting the overall progression of the sepsis diagnostics market.

North America holds the largest market share in the sepsis diagnostics market and is likely to continue its stronghold till 2028. The region’s robust growth can be attributed to the well-developed healthcare infrastructure in the United States and Canada. This resulted in the high adoption rate for sepsis diagnostics instruments in laboratories and diagnostics centers. Above all, the favorable healthcare reimbursement in the region’s countries has influenced the higher penetration of automated sepsis diagnostics analyzers in the market. Therefore, such developments are estimated to support the sepsis diagnostics market’s lucrative growth across North America.

The companies engaged in the sepsis diagnostics market include Immunexpress Inc, Thermo Fisher Scientific Inc, Response Biomedical Corporation, Bruker Corporation, T2 Biosystems Inc, Cytosorbents, F Hoffmann-La Roche, EKF Diagnostics, Becton Dickinson and Company (CR Bard), Abbott Laboratories, Danaher Corporation, Biomerieux SA, and Luminex Corporation.

Due to high industry profitability and unmet medical needs, the threat of new market players is considerably high in the sepsis diagnostics market. Moreover, favorable government policies are encouraging new companies to enter the market. At the same time, some of the major companies have global distribution channels, along with collaborations with large distributors, hospitals, and diagnostic centers. Hence, these companies are anticipated to experience intense competition based on pricing, innovations, and others. This indicates the competition to be high among existing players.

Phone: +44 7441 911839

#sepsis diagnostics #lifesciences #medical devices #consumable #global insights #triton market research

0 notes

waquasuniverse · 3 years

Text

Sepsis Diagnostics Market Highly Favorable to the Growth Rate By 2028

The global sepsis diagnostics market size is expected to reach USD 1.18 billion by 2027, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.5% from 2021 to 2027. The high prevalence of sepsis, the introduction of technologically advanced diagnostic systems, and increasing government initiatives are expected to propel market growth over the forecast…

View On WordPress

0 notes

karishmamulani · 4 years

Text

Sepsis Diagnostics Market 2021-2028 | Business Analysis, Revenue and Prominent Key Players

The global sepsis diagnostics market size is predicted to reach USD 1.03 billion by 2027 according to a new study by Polaris Market Research. The report “Sepsis Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Product (Instruments, Blood Culture Media, Assay Kits & Reagents, Software); By Technology (Microbiology, Molecular Diagnostics, Biomarkers, Immunoassays, Flow Cytometry); By Pathogen (Bacterial Sepsis, Fungal Sepsis, Others); By Testing Type (Laboratory Testing, PoC Testing); By Regions; Segment Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The key factors responsible for the market growth include innovations in biomarker-based sepsis diagnosis; growing medical attention towards ill effects of sepsis and its economic burden; and the development of technologically advanced rapid PoC diagnosis systems. Moreover, the favorable reimburse scenario in developed economies and burgeoning healthcare infrastructure in low and middle-income countries is expected to propel market growth.

The market is fragmented based on product, technology, pathogen, type, and region. In terms of product, the market is segmented into instruments, blood culture media, assay kits and reagents, and software. Based on technology, the market is further bifurcated into microbiology, molecular diagnostics, biomarkers, immunoassays, and flow cytometry. Based on pathogen, the market is classified as bacterial sepsis, fungal sepsis, and others. The type segment is further divided into laboratory testing, and PoC testing.

Download Sample Copy : https://www.polarismarketresearch.com/industry-analysis/global-sepsis-diagnostics-market/request-for-sample

Segment Highlight

· The blood culture media segment accounted for the largest revenue share of the global market as it is used in maximum cases for diagnosis. However, the kits & reagents market segment is expected to witness fastest growth over the forecast period.

· Microbiology technology segment is expected to account for the largest revenue share by the end of 2027 as the technology aids in quantitative identification and detection of microorganisms through culture media tests

· Laboratory testing segment is expected to witness significant growth over the forecast period on account of the increasing number of blood cultures conducted in laboratories across the globe

· North America region is dominating the market, holding a significant market share throughout the forecast period. The presence of major players in the region, industry-academia collaboration, and intellectual capability of the U.S. are major factors responsible for the region’s growth

List of Key Players

· bioMérieux

· Becton Dickinson

· Danaher Corporation

· Abbott Laboratories

· Thermo Fisher Scientific

· EKF Diagnostics

· Roche Diagnostics

· Others

For Further Insights and Segment-Specific Information, Contact a Market Analyst at : https://www.polarismarketresearch.com/industry-analysis/global-sepsis-diagnostics-market/request-for-customization

Polaris Market Research has segmented the sepsis diagnostics market report on the basis of product, technology, pathogen, type, and region:

Sepsis Diagnostics, Product Outlook (Revenue – USD Million, 2016 – 2027)

· Instruments

· Blood Culture Media

· Assay Kits & Reagents

· Software

Sepsis Diagnostics, Technology Outlook (Revenue – USD Million, 2016 – 2027)

· Microbiology

· Molecular Diagnostics

· Immunoassays

· Flow Cytometry

Sepsis Diagnostics, Pathogen Outlook (Revenue – USD Million, 2016 – 2027)

· Bacterial Sepsis

· Gram-Positive Bacteria

· Gram-Negative Bacteria

· Fungal Sepsis

· Others

Sepsis Diagnostics, Type Outlook (Revenue – USD Million, 2016 – 2027)

· Laboratory Testing

· PoC Testing

Sepsis Diagnostics, Regional Outlook (Revenue – USD Million, 2016 – 2027)

· North America (U.S., Canada)

· Europe (France, Germany, UK, Italy, Spain, Netherlands, Austria)

· Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)

· Latin America (Brazil, Mexico, Argentina)

· Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Read More : https://www.medgadget.com/2021/02/sepsis-diagnostics-market-size-is-projected-to-reach-us-1-03-billion-by-2027-exclusive-study-by-polaris-market-research.html

#Sepsis Diagnostics Market

0 notes

latestmarketreport · 5 years

Text

Blood Culture Test Market Drivers, Competitive Landscape, Future Plans And Trends By Forecast 2025

27 March 2020: Global Blood Culture Test Market Research Report includes In-depth Analysis of industry by recent technologies, trends, opportunities, challenges, key players and business strategies considering types, segment, and future analysis. The Blood Culture Test Market Report Provides Growth History, Sales Channel, Manufacturers Profiled in Blood Culture Test Business, Market Share of Product, Application and Regional Scope of Blood Culture Test which makes the research report a helpful resource for marketing people, forecasters, industry executives & consultants, sales, product managers, Strategy Advisor, potential investors to understand the present as well as future market size, situations in terms of growth rate and revenue. This report will help the viewer in Better Decision Making.

The key players profiled in the Blood Culture Test market report are DSM Nutritionals, Jeunesse Global, Hill Pharmaceutical Co Ltd, Blood Culture Test Enhanced Pty Ltd, Andorra Life, ASN Pharmaceutical LLC.

Get a Free Sample Copy of Report @ https://www.millioninsights.com/industry-reports/blood-culture-test-market/request-sample

Global Blood Culture Test Market is projected to reach USD 6.6 billion by 2025 owing to prevalence of blood infections and infectious diseases. Blood culture is a laboratory test wherein the patient’s blood is injected in bottles that contain culture media to determine the existence of infection-producing microorganisms like fungi or bacteria in the patient’s blood. It aims at confirming the existence of microorganisms in the blood, identifying the microbial etiology of the blood infection, helping to determine the infection source like endocarditis, and providing an organism for suspicion of testing and optimization of antimicrobial therapy. This test examines a sample of patient’s blood for yeast or bacteria that might be the root cause of infection. However, the growing demand for enhanced diagnostic techniques for the diagnosis of infectious diseases is expected to boost the blood culture tests market with a CAGR of 8.6%.

The blood infection, if left undetected, may lead to a severe and fatal condition called sepsis. The symptoms of bacteremia or initial bacterial infection are moderate or high fever, breathlessness, chills, muscular pain, palpitations, headache, tachycardia, and nausea. With the growth of infection, the indications also get serious; which may include dehydration, mottled skin, dizziness, confusion, drop in blood pressure, swelling, and organ failure.

Though blood samples are used for the detection of virus in blood, blood culture is essentially used to detect fungi or bacteria. Blood culture test is mostly done in combination with the other diagnostic tests like CBC (complete blood count) or the other chemical analysis. Different techniques like manual/conventional, automated and semi-automated methods could also be used to conduct blood culture test.

This report studies the global Blood Culture Test market status and forecast, categorizes the global Blood Culture Test market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in United States, Europe, China, Japan, South Korea and Taiwan and other regions.

This research report offers a comprehensive analysis of key elements of the Blood Culture Test Market such as potential top key Manufacturers along with their strengths and weaknesses. The Blood Culture Test Market report also comprises some useful strategies and scenario for the new players in the market. While forecasting the growth of the global Blood Culture Test market, various statistical tools were utilized to get an accurate result of the Demographic data.

Avail complete report with TOC and List of Figures @ https://www.millioninsights.com/industry-reports/blood-culture-test-market

Table of Contents

Chapter 1 Blood Culture Test Market Overview

1.1 Blood Culture Test Definition

1.2 Blood Culture Test Market Size Status and Outlook (2013-2028)

1.3 Global Blood Culture Test Market Size Comparison by Region (2013-2028)

1.4 Global Blood Culture Test Market Size Comparison by Type (2013-2028)

1.5 Global Blood Culture Test Market Size Comparison by Application (2013-2028)

1.6 Global Blood Culture Test Market Size Comparison by Sales Channel (2013-2028)

1.7 Blood Culture Test Market Dynamics

1.7.1 Market Drivers/Opportunities

1.7.2 Market Challenges/Risks

1.7.3 Market News (Mergers/Acquisitions/ Expansion)

Chapter 2 Blood Culture Test Market Segment Analysis by Player

Chapter 3 Blood Culture Test Market Segment Analysis by Type

And Continue…

Get More Research Reports Here:

www.marketexpress.over-blog.com

0 notes

aishavass · 1 year

Link

0 notes

medicalresearch · 2 years

Text

Sepsis Diagnostics Market Size, Status Segmentation, Demand, Growth, Trend

According to our new research study on "Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Technology, Method, Test Type, Pathogen, and End User," the market 661.83 million in 2021 to US$ 1,226.52 million by 2028; it is estimated to grow at a CAGR of 9.2% from 2021 to 2028. The report highlights trends prevailing in the market and factors governing the growth of the market. Rising demand for rapid diagnostic tests leading to increasing product launches is expected to accelerate the overall sepsis diagnostics market revenue during the forecast period. However, the lack of skilled professionals limits the market growth.

Additionally, in May 2020, Beckman Coulter announced the launch of its new DxH 690T hematology analyzer with early sepsis indicators in the US. The DxH 690T reported accurate results and improved turnaround time by reducing procedural steps and manual touchpoints, making it an ideal solution to help relieve some of sepsis disease burden. Thus, the rising in demand for rapid diagnostics test led to product launches is expected to drive the sepsis diagnostics market during the forecast period.

On the other hand, the lack of skilled professionals hinders market size and growth. Sepsis diagnosis requires laboratory skills and proficiency to process the collection and investigation of the clinical sample. Sepsis is a life-threatening illness that needs to be diagnosed and treated at the earliest with the help of skilled healthcare professionals. The lack of experienced professionals is a significant concern worldwide. For instance, according to an article published in Young Scientist Journal (YSJ) in April 2018, Sub-Saharan Africa faced a critical shortage of healthcare workers. The deficit is due to the declining emigration of healthcare professionals and the lack of proper healthcare infrastructure and medical graduates, which acts as a restraint on the development of the public health system in that region. Sub-Saharan Africa is considered to have the weakest healthcare system globally. Such restrictions are expected to hamper the growth of the global sepsis diagnostics market over the forecast period.

Technology plays a critical role in healthcare diagnostics as it offers accuracy and saves time and resources and therefore, plays a critical role acting as a future trend in sepsis diagnosis. In sepsis diagnosis process, the identification of causative pathogen is essential in selecting appropriate antibiotic therapy as a part of the treatment. Molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology are majorly used for sepsis diagnostics techniques. Therefore, several companies are investing in point-of-care molecular diagnostics to diagnose bacterial and viral pathogens early and for better patient management. For instance, in October 2020, Immunexpress launched a rapid SeptiCyte, a one-hour molecular diagnostic test for sepsis in Europe on Biocartis' Idylla platform.

Based on product, the sepsis diagnostics market is segmented into instruments, reagents and assays, blood culture media, and software. The blood culture media segment led the market in 2021 and is expected to retain its dominance during the forecast period. According to the Journal of the Academy of Clinical Microbiologists report, blood culture media remains one of the most critical investigations in the sepsis management as it allows identification of the responsible organism for sepsis, appropriate choice of empirical and specific antibiotics, and points towards further investigations for identifying the focus on infection. A blood culture media is recommended for all sepsis patients. Automation in the blood culture system has enabled maximum yield of pathogens in the shortest possible time to improve patient management and save lives. 30–60% of blood culture media in sepsis become positive. The method is highly recommended as it reveals one of the highest levels of evidence in the diagnostic workup of a sepsis patient. Such factors would support the market growth for the blood culture media segment during the forecast period.

Abbott; F. HOFFMANN-LA ROCHE LTD.; Immunexoress, Inc.; BD; Danaher (Beckman Coulter); Luminex Corporation; Thermo Fischer Scientific Inc.; bioMerieux Inc.; T2 Biosystems, Inc.; and Axis-Shield Diagnostics Ltd are among the leading companies operating in the sepsis diagnostics market.

0 notes

marketresearchstrategy · 3 years

Text

Cancer diagnostics Market Share, Industry Growth, Trend, Drivers, Challenges, Key Companies by 2028

Increasing prevalence of various types of cancer across the globe, rising public awareness about importance of early cancer diagnosis, and technological developments in diagnostic systems are some of the key factors fueling global market revenue growth

The global cancer diagnostics market size is expected to reach USD 268.10 Billion in 2028 and register a CAGR of 6.3%, according to the latest report by Reports and Data. Major factors such as increasing demand for cancer diagnostics tests due to easy availability and effectiveness, rising incidence of breast cancer, and initiatives by government and private organizations to create awareness about cancer are driving global market revenue growth.

Cancer is a one of the leading cause of death across the globe. In 2020 alone, around 10 million deaths were reported by World Health Organization. Excess consumption of alcohol, tobacco, unhealthy lifestyle, lack of physical fitness, and other associated diseases like diabetes could lead to various cancer types. Cancer mortality can reduce if detected early. Thus, early detection, screening, and accurate cancer diagnosis are of utmost importance. Cancer diagnostics is one such method that helps to identify different proteins and biomarkers that could help in suspecting presence of cancer. Some of the widely used cancer diagnostics tests are imaging, laboratory tests, genetic tests, biopsy, and endoscopy. Factors such as rising prevalence of breast cancer, ovarian cancer, and lung cancer worldwide, rising geriatric population and increasing healthcare expenditure, improvements in healthcare sector, and increasing demand for effective screening tests are supporting global market revenue growth. In addition, rise in funds for research and development activities and increasing focus of market players to develop more affordable and advanced diagnostics tests and kits is expected to boost market growth going ahead.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3707

The report provides extensive coverage of the supply chain, key players of the industry, consumer base, company profiles, production and consumption rate, primary applications, and other relevant data. It provides an in-depth assessment of the key companies operating in the market along with their company profiles, business overview, production and manufacturing capacity, product portfolio, financial standing, global position, and business expansion plans. It also studies recent mergers and acquisitions, joint ventures, product launches, partnerships, collaborations, and agreements among other. The report also provides insights into new entrants and their strategic alliances to gain a robust footing in the market.

Key Manufacturers in the Global Cancer Diagnostics Market:

Thermo Fischer Scientific, GE Healthcare, Abbott Laboratories, Hologic Inc., Agilent Technologies Inc., Roche Diagnostics, FUJIFILM Corporation, Danaher Corporation, DiaSorin, Myriad Genetics Inc., Siemens Healthineers AG, bioMérieux SA, Bio-Rad Laboratories, Cancer Diagnostics Inc., Vela Diagnostics, Roche Diagnostics, AMOY Diagnostics CO. LTD., Quidel Corporation, Bio SB, Biocartis, and Exact Science.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3707

The report also provides an extensive regional segmentation to offer the readers key insights into the spread of the market over key geographical regions. It covers production and consumption patterns, import/export, supply and demand, consumer demand and behavior, key trends, and presence of key players in each region. The report also offer a country-wise analysis to impart a better understanding of the revenue growth of the market in each region.

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, France, Rest of Europe)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Test Type Outlook (Revenue, USD Billion; 2018-2028)

Imaging

Laboratory Test

Genetic Test

Biopsy

Endoscopy

Others

Application Outlook (Revenue, USD Billion; 2018-2028)

Breast Cancer

Colorectal Cancer

Cervical Cancer

Lung Cancer

Prostate Cancer

Skin Cancer

Blood Cancer

Ovarian Cancer

Others

End-Use Outlook (Revenue, USD Billion; 2018-2028)

Hospitals & Clinics

Diagnostic Centers

Research Institutes

Others

To know more about the report @ https://www.reportsanddata.com/report-detail/cancer-diagnostics-market

Key Questions Addressed in the Report:

What is the market size the global Cancer Diagnostics market is expected to reach over the forecast period? What is the expected CAGR?

What are the key segments of the market?

What are the key products and applications of the Cancer Diagnostics market?

What factors are expected to drive and restrain market growth over the forecast period?

What are the key outcomes of SWOT analysis and Porter’s Five Forces analysis?

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/3707

Thank you for reading our report. The report can be customized based on regional segmentation and competitive landscape. Kindly get in touch with us to know more and our team will ensure the report is well suited to meet your requirements.

Browse more related reports:

Medical Aesthetics Market: https://www.reportsanddata.com/report-detail/medical-aesthetics-market

Disposable Nursing Pad Market: https://www.reportsanddata.com/report-detail/disposable-nursing-pad-market

Breast Pump Market: https://www.reportsanddata.com/report-detail/breast-pump-market

0 notes

kritikarehani · 5 years

Text

Generalized Pustular Psoriasis (GPP) Market Insights, Epidemiology and Market Forecast - 2028

DelveInsight’s Generalized Pustular Psoriasis (GPP) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Generalized Pustular Psoriasis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Generalized Pustular Psoriasis from 2017 to 2028 segmented by the seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market. Geography Covered

The United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2017-2028 Generalized Pustular Psoriasis (GPP) – Disease Understanding and Treatment Algorithm Generalized Pustular Psoriasis (GPP) is a subtype of pustular psoriasis characterized by painful and occasionally disfiguring cutaneous manifestations with sepsis-like systemic symptoms. GPP has been associated with abnormalities in the cytokine (messenger protein) interleukin -36-receptor-antagonist signaling. This is due to recessive IL36RN gene mutations systemic symptoms and systemic upset. GPP is characterized by recurrent acute flares and these flares may result in: headache, rapid pulse rate, loss of appetite and nausea and leg swelling. The DelveInsight’s Generalized Pustular Psoriasis market report gives the thorough understanding of the Generalized Pustular Psoriasis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for GPP in the US, Europe, and Japan.

Generalized Pustular Psoriasis Epidemiology

The GPP epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight’s report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Diagnosed Prevalence Population, Gender Specific Diagnosed Prevalence Population, Age Specific Diagnosed Prevalence Population and Severity Specific Diagnosed Prevalence Population] scenario of Generalized Pustular Psoriasis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017-2028. As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males. According to DelveInsight, total diagnosed prevalent Population of GPP in the 7MM was assessed to be more than 14,000 in 2017, which is expected to increase at a CAGR of XX% for the study period i.e. 2017-2028. Our estimates suggests highest diagnosed prevalence of GPP in the United States with close to 6,000 cases in 2017. Furthermore, among the EU-5 countries, France had the highest diagnosed prevalent population of GPP, followed by Germany and the United Kingdom. On the other hand, Spain was assessed with the lowest diagnosed prevalent population. DelveInsight’s estimations showed that Japan had 2,602 prevalent cases for GPP in 2017. Assessments as per DelveInsight’s analysts showed that the severe cases of GPP accounted for majority of the diagnosed prevalent population across 7MM countries, followed by the number of patients with moderate symptoms. However, the least number of cases were assessed for patient with mild symptoms. Generalized Pustular Psoriasis (GPP)– Drug Chapters This segment of the GPP report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Tremfya (Guselkumab, CNTO1959) is a fully human anti-interleukin (IL)-23 HuCAL monoclonal antibody being marketed by Janssen for Generalized Pustular Psoriasis in Japan. Guselkumab is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. Guselkumab is being developed by HuCAL antibody library technology platform under a licensing agreement of Janssen Pharmaceuticals with MorphoSys. Guselkumab is currently marketed in Japan for the treatment of Generalized Pustular Psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. However, it is not approved in the United States and Europe for pustular psoriasis and erythrodermic psoriasis.

COSENTYX (Secukinumab) is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. Secukinumab inhibits the release of proinflammatory cytokines and chemokines. It is being marketed by Novartis Pharmaceuticals for Generalized Pustular Psoriasis disease.

Lumicef (Brodalumab) is a human interleukin-17 receptor A (IL-17RA) antagonist being marketed by Kyowa Hakko Kirin in Japan for Generalized Pustular Psoriasis, pustular psoriasis, and erythrodermic psoriasis. It is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, and IL-25. In October 2010, Kyowa Hakko Kirin licensed from Kirin-Amgen exclusive rights to develop and commercialize brodalumab in Japan and certain other Asian countries.

Skyrizi (Risankizumab) is a humanized IgG1 monoclonal antibody that binds to the p19 subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. It is being marketed by Abbvie. Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization of Skyrizi globally. Skyrizi is currently under review with the U.S. Food and Drug Administration (FDA) and the company expects a regulatory decision in the first half of 2019.

HUMIRA is a tumor necrosis factor (TNF) blocker being marketed by AbbVie/ Eisai for generalized pustular psoriasis and is available as a subcutaneous Injection. In plaque psoriasis, treatment with HUMIRA may reduce the epidermal thickness and infiltration of inflammatory cells.

Taltz (Ixekizumab) is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor and it inhibits the release of proinflammatory cytokines and chemokines. It is being marketed by Eli Lilly & company for Pustular Psoriasis in Japan.

REMICADE (Infliximab) is a tumor necrosis factor (TNF) blocker being marketed by Mitsubishi Tanabe Pharma in Japan for Generalized Pustular Psoriasis. It neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. In January 2010 REMICADE received the approval from Ministry of Health, Labour and Welfare, Japan for additional indications including pustular psoriasis, Erythrodermic Psoriasis.

Generalized Pustular Psoriasis Market Outlook

The Generalized Pustular Psoriasis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. The market size of GPP in the seven major markets is expected to grow at a CAGR of 10.16% for the study period (2017-2028). The current therapeutic landscape of GPP in the United States is driven by supportive therapies (topical therapies, systemic therapies, biologics and phototherapy). In EU-5 countries, for GPP, the market is same as that of the US, with prescriptions for supportive therapies, due to lack of approved treatment regimens, and together accounted for nearly USD 20.21 million in 2017. In contrast to the US and EU-5 countries, the current therapeutic landscape of GPP in Japan is driven by a number of approved therapies, along with supportive treatment regimens. A modest increase in market size of currently prescribed therapies has been witnessed from 2017 until the launch of emerging therapies in respective countries. The market share is expected to decline post that for current therapies, across the 7MM, owing to the increasing demand for targeted therapies to treat GPP. Among the current treatment regimens, biologics occupy the highest number of prescriptions in the treatment market of GPP. Moreover, combination therapies remain the mainstay in the treatment of GPP, irrespective of the severity of the disease. Generalized Pustular Psoriasis (GPP)– Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. The dynamics of GPP market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2019-2028. With this, several companies have shifted their focus toward this therapeutic area, and two of the therapies are expected to enter the treatment market of GPP during our forecast period, namely BI 655130 (Boehringer Ingelheim) and ANB019 (AnaptysBio). Spesolimab (BI655130) is a new biological entity and first-in-class, intravenous, IL-36 receptor monoclonal antibody being in development for GPP Psoriasis by Boehringer Ingelheim. The drug candidate is the second compound being developed under the company’s immunology division (after risankizumab) and has already shown strong efficacy in early clinical testing with a single dose in patients affected by GPP. The company intends to initiate a Phase III study of BI655130 in Generalized Pustular Psoriasis from May 2019. ANB019 is an interleukin-36-receptor inhibitor monoclonal antibody being in Phase II stage of development by AnaptysBio for GPP. The drug candidate is the company’s most advanced wholly-owned antibody programs which it initially developing as a potentially first-in-class therapy for patients suffering from GPP and palmoplantar pustulosis. AnaptysBio had already demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties of ANB019 in Phase I clinical trial in healthy volunteers. The company has subsequently initiated a 10-patient open-label, multi-dose, single-arm Phase II trial of ANB019 in GPP patients, also referred to as the GALLOP trial, where top-line data are anticipated in mid-2019. Generalized Pustular Psoriasis (GPP) Report Insights

Generalized Pustular Psoriasis Patient Population

Generalized Pustular Psoriasis Therapeutic Approaches

Generalized Pustular Psoriasis Pipeline Analysis

Generalized Pustular Psoriasis Market Size and Generalized Pustular Psoriasis Market Trends

Generalized Pustular Psoriasis Market Opportunities

Impact of upcoming Generalized Pustular Psoriasis Therapies

Generalized Pustular Psoriasis (GPP) Report Key Strengths

10 Years Generalized Pustular Psoriasis Forecast

Generalized Pustular Psoriasis 7MM Coverage

Generalized Pustular Psoriasis Epidemiology Segmentation

Key Cross Competition

Generalized Pustular Psoriasis Market Size

Generalized Pustular Psoriasis Drugs Uptake

Generalized Pustular Psoriasis (GPP) Report Assessment

Generalized Pustular Psoriasis Pipeline Product Profiles

Generalized Pustular Psoriasis Key Products and Generalized Pustular Psoriasis Key Players

Generalized Pustular Psoriasis Market Drivers and Generalized Pustular Psoriasis Market Barriers

Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Generalized Pustular Psoriasis market

Organize sales and marketing efforts by identifying the best opportunities for Generalized Pustular Psoriasis market

To understand the future market competition in the GPP market.

#generalised pustular psoriasis market #generalised pustular psoriasis market research #generalised pustular psoriasis market insight #generalised pustular psoriasis market trends #generalised pustular psoriasis market forecast #generalised pustular psoriasis market share #generalised pustular psoriasis pipeline

0 notes

medicalresearch · 2 years

Text

The sepsis diagnostics market is projected to reach US$ 1,226.52 million by 2028

According to our new research study on “Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Technology, Method, Test Type, Pathogen, and End User,” the market is expected to grow from US$ 661.83 million in 2021 to US$ 1,226.52 million by 2028; it is estimated to grow at a CAGR of 9.2% from 2021 to 2028. The report highlights trends prevailing in the market and factors governing the growth of the market. Rising demand for rapid diagnostic tests leading to increasing product launches is expected to accelerate the overall sepsis diagnostics market revenue during the forecast period. However, the lack of skilled professionals limits the market growth.

Most of the diagnostic tests for sepsis are time-consuming and take up to 72 hours to provide results. In the era of molecular diagnosis for every kind of disease, the demand for rapid diagnostic tests for sepsis is rising. To fulfill this rising demand, many key players operating in the industry put efforts into developing innovative rapid diagnostic tests for sepsis. For instance, in September 2020, Barcelona-based Loop Diagnostics launched a point-of-care diagnosis platform. The platform aimed to replace the traditional methods of blood culture analysis and provide rapid results. Also, it can identify bacterial infections via blood-based markers and provide test results in two hours with a 99% accuracy rate. The cost of the diagnosis with this system is US$ 70. Moreover, the key players developed cost-effective diagnostic tests to overcome all the challenges associated with sepsis diagnosis. For instance, Inflammatix, a pioneering molecular diagnostics company, announced the publication of a health economic model that shows the use of the company's HostDxTM Sepsis test is cost-effective as compare to standard methods. The test was performed on patients suspected of acute respiratory tract infections (ARTI) in Emergency Departments. The study was published in April 2020 in The Journal of Health Economics and Outcomes Research. The model informed hospital clinicians of the potential clinical and economic benefits of widespread adoption of the HostDx Sepsis test. Additionally, in May 2020, Beckman Coulter announced the launch of its new DxH 690T hematology analyzer with early sepsis indicators in the US. The DxH 690T reported accurate results and improved turnaround time by reducing procedural steps and manual touchpoints, making it an ideal solution to help relieve some of sepsis disease burden. Thus, the rising in demand for rapid diagnostics test led to product launches is expected to drive the sepsis diagnostics market during the forecast period.

Sepsis Diagnostics Market, by Region, 2021 (%)

Source: The Insight Partners Analysis More info@ https://www.theinsightpartners.com/reports/sepsis-diagnostics-market

0 notes

marketresearchstrategy · 3 years

Text

Blood Culture Tests Market Size, Share, Industry Growth, Trend, Business Opportunities, Challenges, Drivers and Restraint Research Report by 2027

High demand for rapid diagnostic tests, increasing investments for developing enhanced blood culture tests, and rising prevalence of various infectious diseases are key factors fueling global market growth

The global blood culture tests market size is expected to reach USD 7,709.6 Million in 2028 and register a CAGR of 8.3%, according to the latest report by Reports and Data. Increasing occurrence of Bloodstream Infections (BSI), sepsis and other infectious disorders, and increasing geriatric population are key factors driving global market revenue growth.

A blood culture test is performed in order to detect presence of bacteria, fungus, or other microorganisms that can otherwise lead to several severe infections. Blood culture tests are used to identify blood infection and is often carried out in conjugation with other diagnostic tests. Technological advancements in medical sector, well-established healthcare and diagnostic systems, and rising prevalence of several infectious diseases and increasing risks of sepsis are fueling growth of the blood culture tests market. In addition, increasing investments by well-known healthcare companies and government initiatives related to prevention and control of infectious diseases are key factors boosting global market growth.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1461

The report initially offers market introduction, market overview, product scope, market opportunities, growth prospects, risks, limitations, and key drivers. The report also covers a comprehensive analysis of the competitive landscape with extensive profiling of the key competitors. It covers recent technological advancements, product developments, product launches, mergers and acquisitions, collaborations, joint ventures, and partnerships.

Key Companies in the market include:

Thermo Fisher Scientific, Inc, Becton Dickinson and Company, bioMérieux SA, Cepheid, Inc, Nanosphere, Inc., IRIDICA, Beckman Coulter, Bruker Corporation, and T2 Biosystems.

Regional segmentation comprises of a current and forecast estimation of the market in the key geographical regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report also covers the scope of individual applications and types in each region. The report also covers details about production and consumption patterns, technological developments, revenue growth, market size, market share, key trends and demands influencing market growth in the region, and robust presence of key players in the region.

Market segment analysis:

Method Outlook (Revenue, USD Million; 2017–2027)

Conventional/Manual Blood Culture Method

Automated Blood Culture Method

Product Outlook (Revenue, USD Million; 2017–2027)

Consumables

Blood Culture Media

Aerobic Blood Culture Media

Paediatric Blood Culture Media

Anaerobic Blood Culture Media

Fungi/Yeast Blood Culture Media

Mycobacteria Blood Culture Media

Assay Kits and Reagents

Blood Culture Accessories

Instruments Outlook (Revenue, USD Million; 2017–2027)

Automated Blood Culture Systems

Supporting Laboratory Equipment

Incubators

Colony Counters

Microscopes

Gram Stainers

Software & Services

Technology Outlook (Revenue, USD Million; 2017–2027)

Microarray

PCR

PNA-FISH

Application Outlook (Revenue, USD Million; 2017–2027)

Bacteraemia

Fungemia

End-Use Outlook (Revenue, USD Million; 2017–2027)

Hospital Laboratories

Reference Laboratories

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1461

Regional analysis further covers a country-wise analysis to offer insights into key trends and demands in each major country that might affect the growth of the market in the region.

Regional analysis covers:

North America (U.S.A., Canada)

Europe (U.K., Italy, Germany, France, Rest of Europe)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

To know more about the report @ https://www.reportsanddata.com/report-detail/blood-culture-tests-market

Key Features of the Global Blood Culture Tests Market Report:

Comprehensive analysis of the key players operating in the market along with their SWOT analysis, their business profiles, business overview, market share, global position, and market value

Identification and analysis of significant trends and factors driving revenue growth of the market

Analysis of the competitive landscape along with strategic mergers, expansions, agreements, partnerships, joint ventures, acquisitions, and product launches

Assessment of each market segment along with their growth trends and market revenue contribution

Study of the key regions to pinpoint growth potential and study opportunities, threats, limitations, and risks

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1461

Thank you for reading our report. Customization of this report is available according to the client’s needs. Please get in touch with us to know more about the customization feature and our team will ensure the report is tailored as per your requirements.

Browse More Details:

Healthcare cybersecurity market

Defibrillator market

0 notes

marketresearchstrategy · 3 years

Text

Blood Culture Tests Market Size, Share, Growth, Sales Revenue and Key Drivers Analysis Research Report by 2027